Trials / Active Not Recruiting
Active Not RecruitingNCT06635057
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes During Ramadan
A Phase 4, Multicenter, Multi-Country, Open-Label, Single-Arm Study to Investigate the Effectiveness and Safety of Tirzepatide Once Weekly in Adult Participants With Type 2 Diabetes During Ramadan
- Status
- Active Not Recruiting
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 130 (estimated)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of the study is to investigate whether tirzepatide can be effectively started before Ramadan and used per label in participants with Type 2 Diabetes during the fasting month.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Tirzepatide | Administered SC |
Timeline
- Start date
- 2024-10-11
- Primary completion
- 2026-04-01
- Completion
- 2026-04-01
- First posted
- 2024-10-10
- Last updated
- 2026-01-22
Locations
29 sites across 2 countries: Saudi Arabia, United Arab Emirates
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06635057. Inclusion in this directory is not an endorsement.